An Australian stem cell and regenerative medicine company

ASX Announcements

06 Jul 2018 Appendix 3B-Exercise of Options
01 Jul 2018 Cynata Enters Development Partnership with RCSI
25 Jun 2018 Product Development Program Update & Investor Presentation
20 Jun 2018 Positive 28-day Clinical Trial Data in Cohort B
17 Jun 2018 Research Collaboration with UNSW for Coronary Artery Disease
11 Jun 2018 Positive 6-Month Data from Cohort A in Phase 1 Trial in GvHD
04 Jun 2018 Cleansing Notice
04 Jun 2018 Appendix 3B
30 May 2018 Cynata's MSCs Effective in Model of Diabetic Wounds
29 May 2018 $5.2m placement of shares to Fidelity International
23 May 2018 Enrolment Completed in Cynata's Phase 1 Clinical Trial
22 May 2018 Cleansing Notice
22 May 2018 Appendix 3B-Exercise of Options
15 May 2018 Cleansing Notice
15 May 2018 Appendix 3B-Exercise of Options
07 May 2018 Becoming a substantial holder
07 May 2018 Notice of Allowance from EPO for Patent Application
27 Apr 2018 March 2018 Quarterly Report
24 Apr 2018 Cleansing Notice
24 Apr 2018 Appendix 3B-Exercise of Options
19 Apr 2018 CYP Completes Patent Application related to CAR-T Therapy
12 Apr 2018 Cynata to Present at ARM Investor Day
11 Apr 2018 Further US Patent Granted for Cynata Cymerus Technology
04 Apr 2018 Cleansing Notice
04 Apr 2018 Appendix 3B-Exercise of Options
28 Mar 2018 Cleansing Notice
28 Mar 2018 Appendix 3B-Exercise of Options
27 Mar 2018 FDA Grants Orphan Drug Designation to Cynata for CYP-001
13 Mar 2018 Cleansing Notice
13 Mar 2018 Appendix 3B-Exercise of Options
12 Mar 2018 Updated Top 20 Shareholders
11 Mar 2018 Shaw and Partners Updates Cynata Research Coverage
28 Feb 2018 Cleansing Notice
28 Feb 2018 Appendix 3B-Exercise of Options
26 Feb 2018 Excellent Data from Final Preliminary Evaluation Period
04 Feb 2018 Cynata Engineered MSC Study Review Reveals Promising Results
30 Jan 2018 December 2017 Quarterly Report
23 Jan 2018 Cynata Treats First Patient in Cohort B
22 Jan 2018 Cynata & Celularity Inc Execute MOU
22 Jan 2018 Lapse of Unlisted Options
22 Jan 2018 Encouraging Early Data-Cynata Clinical Trial Proceeds
11 Jan 2018 Release of Securities from Voluntary Escrow
11 Jan 2018 Interview with Cynata Co-Founder Professor Slukvin
17 Dec 2017 End of Year Newsletter & 2018 Outlook
14 Dec 2017 Cynata Receives $1.3m R&D Tax Incentive Refund
11 Dec 2017 Final Preclinical Asthma Study Confirms Efficacy
07 Dec 2017 United States Patent Allowance for Core Cynata Technology
20 Nov 2017 Appendix 3Y-Paul Wotton
20 Nov 2017 Appendix 3B
17 Nov 2017 Results of Annual General Meeting